Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 16, 2014

Primary Completion Date

June 27, 2016

Study Completion Date

June 27, 2016

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Gilteritinib

oral

Trial Locations (5)

Site JP00002, Aichi

Site JP00003, Fukuoka

Site JP00001, Gunma

Site JP00004, Tokyo

Site JP00005, Tokyo